On Tuesday, Shares of SandRidge Energy Inc. (NYSE:SD), gained 1.10% to $0.506.
SandRidge Energy, declared that it has reached a contract to acquire the Piñon Gathering Company, LLC from EIG Global Energy Partners for $48 million cash and $78 million of its 8.75% Senior Secured Notes due 2020. The Piñon Gathering Company, LLC owns about 370 miles of gathering lines supporting the natural gas and CO2 production from the Company’s Piñon field in West Texas. As a result of the transaction, the Company will eliminate minimum volume commitment payments of about $40 million per year, forecasted to continue until 2021 and additional contractual fees thereafter, in addition to secure a planned asset supporting its West Texas natural gas production.
The transaction is anticipated to close in the fourth quarter of 2015, subject to the expiration or termination of the applicable waiting period under the Hart Scott Rodino Act.
SandRidge Energy, Inc. is an oil and natural gas company. The Company operates in three business segments: exploration and production, drilling and oil field services, and midstream services. The exploration and production segment explores for, develops and produces oil and natural gas in the Mid-Continent.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), declined -3.37% to $59.88, during its last trading session.
Bristol-Myers Squibb Company, declared that the U.S. Food and Drug Administration (FDA) has accepted for filing and review three supplemental New Drug Applications (sNDAs) for Daklinza(daclatasvir), an NS5A replication complex inhibitor, for use with sofosbuvir with or without ribavirin. The applications are for the treatment of patients with chronic hepatitis C (HCV) coinfected with human immunodeficiency virus (HIV-1), patients with advanced cirrhosis (counting decompensated cirrhosis), and for patients with post-liver transplant recurrence of HCV.
In the U.S., the FDA grants priority review status when an investigational medicine, if approved, would offer a noteworthy improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. The FDA will review the three Daklinza sNDAs within a six-month timeframe.
Daklinza was initially approved in the U.S. in July 2015 and is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. The new sNDAs accepted by the FDA for review comprise data from the ALLY-1 and ALLY-2 clinical trials. ALLY-2 evaluated the once-daily 12-week combination of Daklinza and sofosbuvir for the treatment of patients with HCV coinfected with HIV-1, a patient population that historically has been challenging to treat, in large part due to the complexities of the overlapping therapeutic regimens used to treat each infection. ALLY-1 evaluated a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for the treatment of patients with HCV with either advanced cirrhosis or post-liver transplant recurrence of HCV.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession.
Shares of Texas Instruments Incorporated (NASDAQ:TXN), inclined 0.66% to $50.46, during its last trading session.
Author and formative assessment expert, Dylan Wiliam, Ph.D., will be the keynote speaker at the Texas Instruments (TI) (TXN) 2016 Teachers Teaching with Technology™ (T3™) International Conference. Wiliam will reveal his methods for improving formative assessment and provide educators with proven strategies for gaining insight into student understanding.
In a varied career, Wiliam has taught in urban public schools, directed a large-scale testing program, served a number of roles in university administration and directed a research program focused on assisting teachers develop their use of assessment in support of learning. He was the co-author of a major review of the research evidence on formative assessment and has subsequently worked with numerous groups of teachers in developing formative assessment practices.
In addition to the keynote, Wiliam will also present sessions on questioning strategies and school leadership that promotes teacher learning.
Texas Instruments Incorporated designs, makes and sells semiconductors to electronics designers and manufacturers across the world. The Company operates through two segments: Analog and Embedded Processing.
Finally, Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF), ended its last trade with 14.76% gain, and closed at $4.12.
Can Fite Biopharma, should head towards $3.5 per share according to 2 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $3 per share. The higher price estimate target is at $4 according to the Analysts.
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.